AR064965A1 - Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa - Google Patents
Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasaInfo
- Publication number
- AR064965A1 AR064965A1 ARP080100238A ARP080100238A AR064965A1 AR 064965 A1 AR064965 A1 AR 064965A1 AR P080100238 A ARP080100238 A AR P080100238A AR P080100238 A ARP080100238 A AR P080100238A AR 064965 A1 AR064965 A1 AR 064965A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- group
- heteroaryl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Abstract
Son inhibidores selectivos de estearoil-coenzima A delta-9 desaturasa (SCD1) con respecto a otras estearoilcoenzima A desaturasas conocidas. Los compuestos de la presente son de utilidad para la prevencion y tratamiento de afecciones relacionadas con la síntesis y metabolismo anormales de lípidos, incluidas enfermedades cardiovasculares, tales como aterosclerosis; obesidad; diabetes; enfermedad neurologica; síndrome metabolico; resistencia a insulina; y esteatosis hepática. Reivindicacion 1: Un compuesto de la formula estructural 1, o una sal farmacéuticamente aceptable de la misma; en la que: cada m es independientemente un numero entero de 0 a 4; cada n es independientemente un numero entero de 0 a 2; cada s es independientemente un numero entero de 1 a 3; cada t es independientemente un numero entero de 1 a 3; q es 0 o 1; r es 0 o 1; Z es O, S, o NR4; X-Y es NCRaRb, CR14-O, CR14-S(O)0-2, o CR13-CRaRb; W es heteroarilo que se selecciona del grupo constituido por las formulas (2); Ar es fenilo, naftilo, o heteroarilo opcionalmente sustituido con de uno a cinco sustituyentes R3; Ra y Rb son cada uno independientemente hidrogeno o alquilo C1-3, en los que el alquilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente a partir de fluor e hidroxi; R1 es heteroarilo que se selecciona del grupo constituido por el grupo de formulas (3) y en las que Rc es -(CH2)mCO2H, -(CH2)mCO2alquilo C13, -(CH2)m-Z-(CH2)pCO2H, o - (CH2)m-Z-(CH2)pCO2alquilo C1-3, en los que cada grupo metileno (CH2) está opcionalmente sustituido con uno o dos sustituyentes que se seleccionan del grupo constituido por alquilo C1-4 , fluor, oxo, e hidroxi; y en las que dicho anillo heteroarilo R1 está opcionalmente sustituido con un sustituyente que se selecciona independientemente del grupo constituido por ciano, halogeno, alquilo C1-4, alcoxi C1-4, (alquil C1- 4)tio(alquil C1-4)sulfonilo y trifluorometilo; cada R2 se selecciona independientemente a partir del grupo constituido por: hidrogeno, halogeno, hidroxi, ciano, amino, nitro, alquilo C1-4, opcionalmente sustituido con de uno a cinco átomos de fluor, alcoxi C1-4, opcionalmente sustituido con de uno a cinco átomos de fluor, alquiltio C1-4, opcionalmente sustituido con de uno a cinco átomos de fluor, alquil C1-4 sulfonilo carboxi, alquiloxi C1-4 carbonilo, y alquil C1-4 carbonilo; cada R3 se selecciona independientemente a partir del grupo constituido por: alquilo C1-6, alquenilo C2-6, (CH2)n-fenilo, (CH2)n-naftilo, (CH2)n-heteroarilo, (CH2)n-heterociclilo, (CH2)ncicloalquilo C3-7, halogeno, nitro, (CH2)nOR4, (CH2)nN(R4)2, (CH2)nC:::N, (CH2)nCO2R4, (CH2)nNR4SO2R4, (CH2)nSO2N(R4)2, (CH2)nS(O)0-2R4, (CH2)nNR4C(O)N(R4)2, (CH2)nC(O)N(R4)2, (CH2)nNR4C(O)R4, (CH2)nNR4CO2R4, (CH2)nC(O)R4, O(CH2)nC(O)N(R4)2, (CH2)s-Z-(CH2)t-fenilo, (CH2)s-Z-(CH2)t-naftilo, (CH2)s-Z-(CH2)t-heteroarilo, (CH2)s-Z-(CH2)t-heterociclilo, (CH2)s-Z-(CH2)t-cicloaiquilo C 3- 7, (CH2)s-Z-(CH2)t-OR4, (CH2)s-Z-(CH2)t-N(R4)2, (CH2)s-Z-(CH2)t- NR4SO2R4, (CH2)s-Z-(CH2)t-C:::N, (CH2)s-Z-(CH2)t-CO2R4, (CH2)s-Z-(CH2)t-SO2N(R4)2, (CH2)s-Z-(CH2)t-S(O)0-2R4, (CH2)s-Z-(CH2)t-NR4C(O)N(R4)2, (CH2)s-Z-(CH2)t-C(O)N(R4)2, (CH2)s-Z-(CH2)t- NR4C(O)R4, (CH2)s-Z-(CH2)t-NR4CO2R4, (CH2)s-Z-(CH2)t-C(O)R4, CF3, CH2CF3, OCF3, y OCH2CF3; en el que fenilo, naftilo, heteroarilo, cicloalquilo, y heterociclilo están opcionalmente sustituidos con de uno a tres sustituyentes que se seleccionan independientemente a partir de halogeno, hidroxi, alquilo C1-4, trifluorometilo, y alcoxi C1-4; y en el que cualquier átomo de carbono tic un metileno (CH2) de R3 está opcionalmente sustituido con de uno a dos grupos que se seleccionan independientemente a partir de fluor, hidroxi, y alquilo C1-4; o dos sustituyentes cuando están en el mismo grupo metileno (CH2) se toman conjuntamente con el átomo de carbono al que están unidos formando un grupo ciclopropilo; cada R4 se selecciona independientemente a partir del grupo constituido por hidrogeno, alquilo C1-6, (CH2)n-fenilo, (CH2)n-heteroarilo, (CH2)n-naftilo, y (CH2)n-cicloalquilo C3-7, en el que alquilo, fenilo, heteroarilo, y cicloalquilo están opcionalmente sustituidos con de uno a tres grupos que se seleccionan independientemente a partir de halogeno, trifluorometilo, alquilo C1-4 y alcoxi C1-4; o dos grupos 4 junto con el átomo al que están unidos forman un sistema anular cíclico monocíclico o bicíclico de 4 a 8 miembros que opcionalmente contiene un heteroátomo adicional que se selecciona a partir de O, S, NH, y Nalquilo C1-4; R5, R6, R7, R8, R9, R10, R11, y R12 son cada uno independientemente hidrogeno, fluor, o alquilo C1-3, en los que el alquilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente a partir de fluor e hidroxi; R13 es hidrogeno, alquilo C1-3, fluor, o hidroxi; y cada R14 es hidrogeno o alquilo C1-3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89767507P | 2007-01-26 | 2007-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064965A1 true AR064965A1 (es) | 2009-05-06 |
Family
ID=39644071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100238A AR064965A1 (es) | 2007-01-26 | 2008-01-18 | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
Country Status (11)
Country | Link |
---|---|
US (2) | US7582633B2 (es) |
EP (1) | EP2108015A4 (es) |
JP (1) | JP2010516714A (es) |
CN (1) | CN101641347A (es) |
AR (1) | AR064965A1 (es) |
AU (1) | AU2008209295A1 (es) |
CA (1) | CA2676199A1 (es) |
CL (1) | CL2008000198A1 (es) |
PE (1) | PE20081704A1 (es) |
TW (1) | TW200838533A (es) |
WO (1) | WO2008089580A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2027121A1 (en) * | 2006-05-22 | 2009-02-25 | Merck Frosst Canada Ltd. | Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2032566A4 (en) * | 2006-06-12 | 2009-07-08 | Merck Frosst Canada Ltd | AZETIDINE DERIVATIVES AS DELTA-9 DEATURASE STÉAROYL-COENZYME INHIBITORS |
EP2032570A4 (en) | 2006-06-13 | 2010-10-27 | Merck Frosst Canada Ltd | AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
AU2007283401A1 (en) * | 2006-08-09 | 2008-02-14 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
TW200826936A (en) | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
CA2683948A1 (en) * | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2152719A4 (en) * | 2007-05-23 | 2011-01-19 | Merck Frosst Canada Ltd | BICYCLIC HETEROAROMATIC COMPOUNDS AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS |
WO2008157844A1 (en) * | 2007-06-21 | 2008-12-24 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
US20100197692A1 (en) * | 2007-07-20 | 2010-08-05 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
WO2010043052A1 (en) * | 2008-10-17 | 2010-04-22 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US20100160323A1 (en) * | 2008-12-23 | 2010-06-24 | Alexander Bischoff | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE |
AU2010215035B2 (en) | 2009-02-17 | 2014-06-12 | Merck Canada Inc. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
US8383643B2 (en) | 2009-07-28 | 2013-02-26 | Merck Canada Inc. | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
JPWO2011093501A1 (ja) * | 2010-02-01 | 2013-06-06 | 日本ケミファ株式会社 | Gpr119作動薬 |
FR2958935B1 (fr) | 2010-04-19 | 2012-06-22 | Pf Medicament | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
US8530461B2 (en) * | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
CN104768549A (zh) | 2012-05-22 | 2015-07-08 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 未分化细胞的选择性抑制剂 |
WO2014086704A1 (en) * | 2012-12-03 | 2014-06-12 | F. Hoffmann-La Roche Ag | Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1) |
JP2019533022A (ja) * | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
KR20190108118A (ko) | 2017-01-06 | 2019-09-23 | 유마니티 테라퓨틱스, 인크. | 신경계 장애의 치료를 위한 방법 |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0876366T3 (da) | 1996-01-15 | 2001-11-05 | Janssen Pharmaceutica Nv | Angiogenese-inhiberende pyridazinaminer |
US20050119251A1 (en) | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
JP4838128B2 (ja) * | 2003-07-30 | 2011-12-14 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピペラジン誘導体および治療剤としてのその用途 |
US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
BRPI0412343A (pt) | 2003-07-30 | 2006-09-05 | Xenon Pharmaceuticals Inc | derivados de piridazina e seu uso como agentes terapêuticos |
US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
AU2005286647A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
BRPI0515488A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de heterocìclicos e seu uso como agentes terapêuticos |
EP2269610A3 (en) | 2004-09-20 | 2011-03-09 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
JP5080256B2 (ja) | 2004-09-20 | 2012-11-21 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 二環式複素環誘導体およびステアロイル−CoAデサチュラーゼ(SCD)のインヒビターとしてのそれらの使用 |
MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
CA2580845A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
GT200600046A (es) * | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
WO2006125181A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
AU2006255465A1 (en) | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
AU2006272334A1 (en) * | 2005-07-20 | 2007-01-25 | Merck Frosst Canada Ltd | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
JP2009510132A (ja) | 2005-10-05 | 2009-03-12 | メルク フロスト カナダ リミテツド | ロイコトリエン生合成の阻害剤としての置換キノリン |
EP1951731A4 (en) | 2005-11-15 | 2010-07-07 | Merck Frosst Canada Ltd | AZACYCLOHEXANE DERIVATIVES AS DELTA-9 DEATURASE STÉAROYL-COENZYME INHIBITORS |
CA2632936A1 (en) | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2027121A1 (en) | 2006-05-22 | 2009-02-25 | Merck Frosst Canada Ltd. | Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2032566A4 (en) | 2006-06-12 | 2009-07-08 | Merck Frosst Canada Ltd | AZETIDINE DERIVATIVES AS DELTA-9 DEATURASE STÉAROYL-COENZYME INHIBITORS |
EP2032570A4 (en) | 2006-06-13 | 2010-10-27 | Merck Frosst Canada Ltd | AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
AU2007283401A1 (en) | 2006-08-09 | 2008-02-14 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
EP2076509A4 (en) | 2006-10-20 | 2011-02-16 | Merck Frosst Canada Ltd | AZACYCLOALCANE DERIVATIVES AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS |
TW200826936A (en) | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
-
2008
- 2008-01-18 AR ARP080100238A patent/AR064965A1/es not_active Application Discontinuation
- 2008-01-21 TW TW097102225A patent/TW200838533A/zh unknown
- 2008-01-23 PE PE2008000179A patent/PE20081704A1/es not_active Application Discontinuation
- 2008-01-24 EP EP08706318A patent/EP2108015A4/en not_active Withdrawn
- 2008-01-24 CA CA002676199A patent/CA2676199A1/en not_active Abandoned
- 2008-01-24 CN CN200880009274A patent/CN101641347A/zh active Pending
- 2008-01-24 CL CL200800198A patent/CL2008000198A1/es unknown
- 2008-01-24 JP JP2009546626A patent/JP2010516714A/ja not_active Withdrawn
- 2008-01-24 AU AU2008209295A patent/AU2008209295A1/en not_active Abandoned
- 2008-01-24 WO PCT/CA2008/000171 patent/WO2008089580A1/en active Application Filing
- 2008-01-25 US US12/011,309 patent/US7582633B2/en not_active Expired - Fee Related
-
2009
- 2009-07-07 US US12/498,476 patent/US20090270434A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2008089580A1 (en) | 2008-07-31 |
EP2108015A4 (en) | 2011-06-01 |
TW200838533A (en) | 2008-10-01 |
CA2676199A1 (en) | 2008-07-31 |
US20090270434A1 (en) | 2009-10-29 |
CN101641347A (zh) | 2010-02-03 |
JP2010516714A (ja) | 2010-05-20 |
PE20081704A1 (es) | 2008-12-07 |
US20080182838A1 (en) | 2008-07-31 |
EP2108015A1 (en) | 2009-10-14 |
CL2008000198A1 (es) | 2008-05-30 |
AU2008209295A1 (en) | 2008-07-31 |
US7582633B2 (en) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064965A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa | |
AR064026A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
CR9267A (es) | Derivados de quinazolina para el tratamiento de la tuberculosis latente | |
RU2018121499A (ru) | Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1 | |
AR067396A1 (es) | Compuesto derivado de imidazo(1,2-a)piridin-2-ilmetil piperidina sustituida sal hidrocloruro del mismo uso del compuesto o de la sal hidrocloruro para la preparacion de un medicamento y composiciones farmaceuticas que los comprende | |
AR082763A1 (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer | |
AR073209A1 (es) | Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen. | |
AR067886A1 (es) | Derivados de acido azabifenilaminobenzoico | |
RU2010148570A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
JP2016506961A5 (es) | ||
RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
JP2014520888A5 (es) | ||
AR074238A1 (es) | Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende | |
AR072249A1 (es) | Inhibidores de amida hidrolasa de acido graso. usos. metodos. | |
AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
RU2007148504A (ru) | Индановые производные в качестве модуляторов ионных каналов | |
RU2009122375A (ru) | Новые производные 1,2-дигидрохинолина, имеющие в качестве заместителей (замещенный фенил)- халькоген-(низшую алкильную) группу и фенильную группу, введенную через сложноэфирную группу | |
AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica | |
AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
GB201201744D0 (en) | Novel compounds | |
PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |